Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Neurological manifestations of Behçet's disease: Evaluation of 40 patients treated by cyclophosphamide
Revue Neurologique, Volume 168, No. 4, Year 2012
Notification
URL copied to clipboard!
Description
Introduction: Neurological manifestations in Behçet's disease represent between 4 to 49% of systemic manifestations and remain, in the long term, the leading cause of morbidity and mortality. Methods: Retrospective series of 40 severe Neurobehçet cases fulfilling the International Study Group criteria for Behçet's disease were consecutively recruited over a period from June 2004 to December 2010. All patients had clinical and ophthalmologic examinations; they underwent laboratory and imaging investigations. They received corticosteroids and cyclophosphamide as initial bolus of 600 mg/m2 of BSA in the 1st, 2nd, 4th, 6th and 8th day followed by a bolus of 600 mg/m2 BSA every 2 months for 2 years. Antithrombotic therapy was given to patients with cerebral deep venous thrombosis. Patient follow-up and tolerance to treatment were analyzed. Results: The average age at diagnosis was 34 ± 13 years, with a sex-ratio of 1.78. The clinical presentation was dominated by the meningoencephalitis in 48.8% of cases, cerebral deep venous thrombosis in 43.6% of cases and myelopathy in 7.7% of cases. The 40 patients receiving cyclophosphamide bolus, despite two aggravated cases, evolved positively with clinical improvement and good tolerance. Conclusion: The demographic and clinical aspects of our series are similar to those reported in the literature. In contrast to previously reported cases of a poor prognosis in severe neurobehçet's disease, our study suggests that immediate and aggressive treatment by cyclophosphamide may ameliorate the prognosis. However, a multicenter study is needed to confirm the possible efficacy of cyclophosphamide and further assess the long-term tolerance. © 2011 Elsevier Masson SAS. All rights reserved.
Authors & Co-Authors
Ait Ben Haddou, Elhachmia
Morocco, Agdal Rabat
Ibn Sina Hospital, Agdal Rabat
Imounan, Fatima
Morocco, Agdal Rabat
Ibn Sina Hospital, Agdal Rabat
Regragui, Wafaa
Morocco, Agdal Rabat
Ibn Sina Hospital, Agdal Rabat
Mouti, O.
Unknown Affiliation
Benchakroune, Nadia
Morocco, Agdal Rabat
Ibn Sina Hospital, Agdal Rabat
Abouqal, Redouane
Morocco, Rabat
Faculté de Médecine et de Pharmacie de Rabat
Benomar, Ali
Morocco, Agdal Rabat
Ibn Sina Hospital, Agdal Rabat
Morocco, Rabat
Faculté de Médecine et de Pharmacie de Rabat
Yahyaoui, Mohamed
Morocco, Agdal Rabat
Ibn Sina Hospital, Agdal Rabat
Statistics
Citations: 35
Authors: 8
Affiliations: 2
Identifiers
Doi:
10.1016/j.neurol.2011.09.006
ISSN:
00353787
Research Areas
Health System And Policy
Study Design
Cohort Study